Forendo Pharma initiates phase I study for potential new, targeted treatment for endometriosis

Turku, Finland, July 4 2018: Forendo Pharma, a drug development company focusing on novel oral
treatments for endometriosis patients, today announces it has received clinical trial authorisation (CTA)
from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) to commence a study
for its lead program FOR-6219.

Read more

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...

GET IN TOUCH